SG11202009215PA - Continuous administration of pharmaceutical composition for treatment of neurodegenerative disorders - Google Patents
Continuous administration of pharmaceutical composition for treatment of neurodegenerative disordersInfo
- Publication number
- SG11202009215PA SG11202009215PA SG11202009215PA SG11202009215PA SG11202009215PA SG 11202009215P A SG11202009215P A SG 11202009215PA SG 11202009215P A SG11202009215P A SG 11202009215PA SG 11202009215P A SG11202009215P A SG 11202009215PA SG 11202009215P A SG11202009215P A SG 11202009215PA
- Authority
- SG
- Singapore
- Prior art keywords
- treatment
- pharmaceutical composition
- neurodegenerative disorders
- continuous administration
- administration
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1850327 | 2018-03-23 | ||
| PCT/SE2019/050260 WO2019182506A1 (en) | 2018-03-23 | 2019-03-22 | Continuous administration of pharmaceutical composition for treatment of neurodegenerative disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202009215PA true SG11202009215PA (en) | 2020-10-29 |
Family
ID=66041617
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202009215PA SG11202009215PA (en) | 2018-03-23 | 2019-03-22 | Continuous administration of pharmaceutical composition for treatment of neurodegenerative disorders |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11547689B2 (en) |
| EP (1) | EP3768263A1 (en) |
| JP (1) | JP2021519272A (en) |
| KR (1) | KR20200136008A (en) |
| CN (1) | CN112261940B (en) |
| AU (1) | AU2019237857A1 (en) |
| IL (1) | IL277553A (en) |
| PH (1) | PH12020551527A1 (en) |
| SG (1) | SG11202009215PA (en) |
| WO (1) | WO2019182506A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016258179B2 (en) | 2015-05-06 | 2021-07-01 | Synagile Corporation | Pharmaceutical suspensions containing drug particles, devices for their administration, and methods of their use |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9004348D0 (en) | 1990-02-27 | 1990-04-25 | Orion Yhtymae Oy | New use of catechol derivatives and their physiologically acceptable salts and esters |
| SE9203594D0 (en) | 1992-11-30 | 1992-11-30 | Christer Nystroem | DISPERSA SYSTEM MEDICINAL PRODUCT |
| US20080118556A1 (en) * | 1998-11-02 | 2008-05-22 | Elan Corporation, Plc | Modified Release of Compositions Containing a Combination of Carbidopa, Levodopa and Entacapone |
| FI109453B (en) | 1999-06-30 | 2002-08-15 | Orion Yhtymae Oyj | Pharmaceutical composition |
| AU2004270174B2 (en) | 2003-08-29 | 2010-05-20 | Transform Pharmaceuticals, Inc. | Pharmaceutical compositions and method of using levodopa and carbidopa |
| EP1796687A2 (en) * | 2004-09-14 | 2007-06-20 | Elixir Pharmaceuticals, Inc. | Combination therapy for controlled carbohydrate digestion |
| CN101132777A (en) * | 2004-12-20 | 2008-02-27 | 科利吉姆制药公司 | Pharmaceutical compositions for sleep disorders |
| US20060222703A1 (en) | 2005-04-01 | 2006-10-05 | Iprbox Oy | Pharmaceutical composition and preparation method thereof |
| AU2007267135B2 (en) | 2006-05-31 | 2013-03-07 | AbbVie Pharmaceuticals GmbH | Long term 24 hour intestinal administration of levodopa/carbidopa |
| EP2104424A4 (en) | 2006-10-30 | 2011-06-15 | Wockhardt Research Center | Pharmaceutical compositions comprising entacapone, levodopa, and carbidopa |
| ATE510537T1 (en) | 2008-02-06 | 2011-06-15 | Wockhardt Research Center | PHARMACEUTICAL COMPOSITIONS OF ENTACAPONE, LEVODOPA AND CARBIDOPA WITH IMPROVED BIOAVAILABILITY |
| MX340249B (en) * | 2008-08-15 | 2016-07-01 | Depomed Inc | Gastric retentive pharmaceutical compositions for treatment and prevention of cns disorders. |
| EA026419B1 (en) * | 2010-03-04 | 2017-04-28 | Орион Корпорейшн | Use of levodopa, carbidopa and entacapone for treating parkinson's disease |
| BR112013011685B1 (en) | 2010-11-15 | 2022-03-03 | Neuroderm Ltd | Pharmaceutically acceptable liquid composition and transdermal patch |
| WO2012147099A1 (en) | 2011-04-25 | 2012-11-01 | Suven Nishtaa Pharma Pvt. Ltd. | Pharmaceutical compositions of levodopa, carbidopa and entacapone |
| PT3782617T (en) | 2014-09-04 | 2024-02-29 | Lobsor Pharmaceuticals Ab | Pharmaceutical gel compositions comprising levodopa, carbidopa and entacapon |
| WO2017039525A1 (en) * | 2015-09-04 | 2017-03-09 | Lobsor Pharmaceuticals Aktiebolag | Method of treating a dopamine related disorder in a subject by administering levodopa, in combination with a dopamine decarboxylase inhibitor and a catechol-o-methyltransferase inhibitor |
-
2019
- 2019-03-22 KR KR1020207030580A patent/KR20200136008A/en not_active Application Discontinuation
- 2019-03-22 CN CN201980034384.XA patent/CN112261940B/en active Active
- 2019-03-22 AU AU2019237857A patent/AU2019237857A1/en active Pending
- 2019-03-22 SG SG11202009215PA patent/SG11202009215PA/en unknown
- 2019-03-22 US US17/040,511 patent/US11547689B2/en active Active
- 2019-03-22 EP EP19715590.6A patent/EP3768263A1/en active Pending
- 2019-03-22 JP JP2020551353A patent/JP2021519272A/en active Pending
- 2019-03-22 WO PCT/SE2019/050260 patent/WO2019182506A1/en active Application Filing
-
2020
- 2020-09-22 PH PH12020551527A patent/PH12020551527A1/en unknown
- 2020-09-23 IL IL277553A patent/IL277553A/en unknown
-
2022
- 2022-11-04 US US17/981,092 patent/US20230157989A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| PH12020551527A1 (en) | 2021-07-19 |
| US11547689B2 (en) | 2023-01-10 |
| EP3768263A1 (en) | 2021-01-27 |
| JP2021519272A (en) | 2021-08-10 |
| US20210015782A1 (en) | 2021-01-21 |
| CN112261940A (en) | 2021-01-22 |
| IL277553A (en) | 2020-11-30 |
| WO2019182506A1 (en) | 2019-09-26 |
| KR20200136008A (en) | 2020-12-04 |
| CN112261940B (en) | 2024-02-27 |
| US20230157989A1 (en) | 2023-05-25 |
| AU2019237857A1 (en) | 2020-10-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202004025B (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases | |
| SG11202106160WA (en) | Pharmaceutical composition for prevention or treatment of cancer comprising weissella cibaria wikim28 as active ingredient | |
| SG11202104923YA (en) | Pharmaceutical combination for treatment of cancer | |
| IL272601A (en) | Pharmaceutical compositions for the treatment of ophthalmic conditions | |
| GB201610056D0 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders and osteoarthritis | |
| ZA202002166B (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | |
| IL279397A (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases | |
| KR102228571B9 (en) | Drug delivery system for treatment of psychosis or central nervous system diseases | |
| EP4081201A4 (en) | Pharmaceutical composition for treatment or prevention of multiple inflammatory disorders | |
| GB201911868D0 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | |
| GB201610055D0 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders and osteoarthritis | |
| EP3841086A4 (en) | Pharmaceutical compounds for the treatment of complement factor d medical disorders | |
| IL269400A (en) | Drugs and compositions for the treatment of ocular disorders | |
| IL286677A (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | |
| IL286688A (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | |
| IL257336B (en) | Compounds and pharmaceutical compositions for prevention or treatment of parasitic diseases | |
| IL277553A (en) | Continuous administration of pharmaceutical composition for treatment of neurodegenerative disorders | |
| EP3338771A4 (en) | Pharmaceutical composition of a combination of tramadol-etoricoxib hydrochloride for the treatment of pain | |
| IL286685A (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | |
| GB201702603D0 (en) | Novel compositions and pharmaceutical compositions thereof for the treatment of inflammatory disorders | |
| SI3586832T1 (en) | Pharmaceutical composition for the treatment of constipation | |
| PL3650024T3 (en) | Pharmaceutical composition for nasal administration comprising rifampicins for treating dementia | |
| GB201807222D0 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammation disorders | |
| GB201814764D0 (en) | Pharmaceutical compositions for the treatment of proteinopathies | |
| GB201817344D0 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases |